Organ Transplant Immunosuppressant Drugs Market by Drug Classes (Calcineurin Inhibitors: Tacrolimus and Cyclosporine, Antiproliferative Agents: Mycophenolate Mofetil, Mycophenolate Sodium and Azathioprine, mTOR Inhibitor: Sirolimus, and Steroids: Prednisone) and Transplanted organ Types (Bone Marrow, Heart, Kidney Liver and Lung Transplants) and Forecast 2017-2021

Organ Transplant Immunosuppressant Drugs Market by Drug Classes (Calcineurin Inhibitors: Tacrolimus and Cyclosporine, Antiproliferative Agents: Mycophenolate Mofetil, Mycophenolate Sodium and Azathioprine, mTOR Inhibitor: Sirolimus, and Steroids: Prednisone) and Transplanted organ Types (Bone Marrow, Heart, Kidney Liver and Lung Transplants) and Forecast 2017-2021

Immunosuppressant drugs or anti-rejection drugs are a class of drugs that suppress or reduce the strength of the body’s immune system. There are 2 types of immunosuppressants: Induction drugs: Powerful antirejection medicine used at the time of transplant and Maintenance drugs: antirejection medications used for the long term. Organ transplant immunosuppressant drugs are used by patients who are undergoing or have undergone an organ transplant for kidney, liver, heart, etc. due to organ dysfunction caused due to cancer, severe injuries to the organ, metabolic disorders such as renal failure and/or genetic disorders. Increasing number of organ transplantations globally and its demand for advanced immunosuppressant drugs for improved organ tolerance are the key factors driving the growth of the global organ transplant immunosuppressant drugs market. There are usually four classes of maintenance drugs: calcineurin inhibitors: tacrolimus and cyclosporine, antiproliferative agents: mycophenolate mofetil, mycophenolate sodium and azathioprine, mTOR inhibitor: sirolimus, and steroids: prednisone.

The global organ transplant immunosuppressant drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug classes (calcineurin inhibitors: tacrolimus and cyclosporine, antiproliferative agents: mycophenolate mofetil, mycophenolate sodium and azathioprine, mTOR inhibitor: sirolimus, and steroids: prednisone) and transplanted organ types (bone marrow, heart, kidney liver and lung transplants), and forecasts growth trends (CAGR% – 2017 to 2021).

The global organ transplant immunosuppressant drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global organ transplant immunosuppressant drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global organ transplant immunosuppressant drugs market and included in this report are AbbVie, Inc., Astellas Pharma, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and Veloxis Pharmaceuticals A/S.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Organ Transplant Immunosuppressant Drugs Market

1. Drug Class
1.1. Antibodies
1.2. Antiproliferative Agents
1.3. Calcineurin Inhibitors
1.4. mTOR Inhibitors
1.5. Steroids

2. Organ Type
2.1. Bone Marrow Transplant
2.2. Heart Transplant
2.3. Kidney Transplant
2.4. Liver Transplant
2.5. Lung Transplant
2.6. Other Transplants

3. Company Profiles
3.1. AbbVie, Inc.
3.2. Allergan plc.
3.3. Astellas Pharma, Inc.
3.4. Bristol-Myers Squibb Company
3.5. F. Hoffmann-La Roche Ltd.
3.6. GlaxoSmithKline plc
3.7. Janssen Pharmaceutical
3.8. Novartis AG
3.9. Pfizer, Inc.
3.10. Sanofi S.A.
3.11. Veloxis Pharmaceuticals

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*